Of the 24 genes identified in this study as being involved in the irinotecan pathway of colorectal cancer, the expression levels of CES1 and CES2 (involved in the conversion of the pro-drug to irinotecan) were diminished by approximately 25%. The gene discussed is CES1; the disease is colorectal cancer.